fbpx Skip to main content

Member Resources

Check this page for the latest information, guidance and updates from Biocom, public policy and our partners regarding the novel coronavirus (COVID-19) as it relates to California’s life science industry.

Policy Announcements  Business Continuity  Events & Resources

Policy Announcements

7/13/20: Governor Throttles Back Reopening

4/28/20: State Revises Critical Infrastructure Workers List:
On Tuesday the Newsom Administration revised its California Critical Infrastructure Workers list.  The change, effective immediately, appears to more clearly call out life science facilities broadly as essential workplaces.  As always, please consult proper counsel for applicability to your specific circumstance.


7. Workers in other medical and life science facilities (including Ambulatory Health and Surgical, Blood Banks, Clinics, Community Mental Health, Comprehensive Outpatient rehabilitation, End Stage Renal Disease, Health Departments, Home Health care, Hospices, Hospitals, Long Term Care, Organ Pharmacies, Procurement Organizations, Psychiatric, Residential, Rural Health Clinics and Federally Qualified Health Centers, and retail facilities specializing in medical goods and supplies, including cannabis).

8. Workers for health manufacturing (including life science companies, and companies that have shifted production to medical supplies), materials and parts suppliers, technicians, logistics and warehouse operators, printers, packagers, and distributors of medical equipment (including those who test and repair), personal protective equipment (PPE), isolation barriers, medical gases, pharmaceuticals (including materials used in radioactive drugs, and cannabis products), dietary supplements, blood and blood products, vaccines, testing materials, laboratory supplies, cleaning, sanitizing, disinfecting or sterilization supplies, personal hygiene products, and tissue and paper towel products.



Bay Area

  • San Francisco Department of Public Health Updates
  • April 27, 2020 Update: The Public Health Officers of the Counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara as well as the City of Berkeley issued a joint statement that later this week they will issue revised shelter-in-place orders that will largely keep existing shelter in place orders in place through the end of May, with a “limited easing of specific restrictions for a small number of lower-risk activities.” The release states “The Health Officers will also release a set of broad indicators that will be used to track progress in preparedness and response to COVID-19, in alignment with the framework being used by the State of California.”
  • March 31, 2020 Update: The six counties in the San Francisco Bay Area that initially issued shelter-in-place orders on March 16th extended and revised their orders with further restrictions, including limitations on construction activity. While pharmaceutical and biotechnology companies are still considered essential and may continue to operate as normal while practicing social distancing, construction will now be limited to: healthcare projects directly related to addressing the COVID-19 pandemic, housing and mixed use projects that include a minimum of 10% affordable units, projects that “provide services to vulnerable populations,” and developments that are required to “maintain the safety, sanitation, and habitability of residence and commercial buildings.”
  • For those Bay Area companies who will maintain operations under the revised 3/31 local emergency order, please be aware of the following language regarding social distancing requirements (item #5 on the emergency orders). A social distancing protocol template can be found here. All Essential Businesses are strongly encouraged to remain open. But Essential Businesses are directed to maximize the number of employees who work from home. Essential Businesses may only assign those employees who cannot perform their job duties from home to work outside the home. All Essential Businesses shall prepare, post, and implement a Social Distancing Protocol at each of their facilities at which they are maintaining operations, as specified in Section 13.h. Businesses that include an Essential Business component at their facilities alongside non-essential components must, to the extent feasible, scale down their operations to the Essential Business component only; provided, however, that mixed retail businesses that are otherwise allowed to operate under this Order may continue to stock and sell non-essential products. Essential Businesses must follow industry-specific guidance issued by the Health Officer related to COVID-19. Alameda County | Contra Costa County | Marin County | San Francisco City and County | San Mateo County | Santa Clara County | City of Berkeley.

San Diego

Los Angeles

Orange County

Business Continuity

Updates on possible disruptions to the daily and future operations, travel and supply chains of our California life science members.

SBA LOAN SUPPORT: Receive up to $10M through Divvy’s expedited SBA PPP loan process. Learn more about Biocom and Divvy’s partnership here.

Supply Chain

Travel & Workplace


Environmental Health & Safety

Funding for COVID-19 Solutions

Events & Resources

Check back often for Biocom workshops and events that address evolving COVID-19 concerns, as well as any updates or possible cancelations of larger events and conferencesView our updated events policy here.

A message from Admiral Giroir

Wednesday, October 14, 2020
Admiral Groir shares a message to California’s life science industry regarding their work addressing the COVID-19 pandemic.

Download Message

Webinar: Clinical Trials in the Era of COVID-19: Insights from the FDA

Tuesday, August 11, 2020
Biocom, in partnership with the Food & Drug Administration (FDA), is hosting a webinar on conducting clinical trials during the ongoing COVID-19 pandemic.

Download Webinar

Working Through FDA’s Emergency Use Authorization (EUA) Pathway in the Era of COVID-19

On Tuesday, May 5, Biocom hosted a one-hour webinar designed for companies and entrepreneurs looking to launch new Personal Protective Equipment (PPE), Diagnostic Tests and Other Medical Devices to combat the COVID-19 Pandemic. The recording of the webinar, which can be downloaded using the link below, goes over how companies can navigate the FDA’s EUA Pathway to meet the ever-increasing demand to bring new solutions and additional manufacturing capacity to fight this pandemic.

Download Webinar

Breakfast with Biocom: COVID-19 Vaccine Development with Inovio Pharmaceuticals

Listen to an exclusive fireside chat with Inovio Pharmaceuticals, a San Diego company leading the way in COVID-19 vaccine development. Dr. Kate E. Broderick, Senior VP, R&D Pharmaceuticals and nCoV Project Lead at Inovio Pharmaceuticals speaks with Li Chen, VP and General Manager of Synthetic Biology and Molecular Biology at Thermo Fisher Scientific about the major differences in the company’s innovative technology compared to traditional vaccine development.

Regulatory Rundown: Week of April 6-10

Learn about key regulatory takeaways from recent coronavirus news and developments.

Read more

Coronavirus Roundtable: HHSA Response and Company Prevention Measures

How is your company preparing for and responding to the novel coronavirus (COVID-19)? Read takeaways from Biocom’s March 6th event that brought together industry Environmental Health & Safety managers from companies of all sizes in San Diego to discuss just that.

Read summary

Biocom Japan Updates

  • Telecommuting and virtual meetings: As of March 1, 46% of companies in Japan are to some extent telecommuting or conducting meetings online. Many large companies will continue to telecommute through mid-March and reassess at that time.
  • Events: Many events are getting cancelled, including BioAsia (3/10-3/11), while some others being postponed. BioJapan, scheduled for October, is still taking place at this time. Members should remain in close contact with event organizers.